Cut-Off Values of Specific IgE and Skin Prick Test to Predict Oral Food Challenge Positivity in Children with Cow’s Milk Allergy

Nurşen Ciğerci Günaydın1, Sanem Eren Akarcan1, Figen Gülen1, Cem Murat Batı1, Remziye Tanac1, Mesude Atasever1, Esen Demir1

1Division of Pediatric Allergy and Immunology, Department of Pediatrics, Namık Kemal University Faculty of Medicine, Tekirdağ, Turkey
2Division of Pediatric Allergy and Immunology, İzmir Tepecik Training and Research Hospital, İzmir, Turkey
3Division of Pediatric Pulmonology, Department of Pediatrics, Ege University Faculty of Medicine, İzmir, Turkey

What is already known on this topic?

- The cut-off values for the cow’s milk-skin prick test (CM-SPT) diameters and CM-specific IgE measurements are used to predict the result of the oral food challenge test in the diagnosis of cow’s milk allergy (CMA).

What this study adds on this topic?

- The diagnostic power of SPT was determined to be higher when compared to CM-sIgE in the diagnosis of CMA in patients ≤2 years of age, whereas 2 tests had similar diagnostic power in patients >2 years of age. Additionally, the significant cut-off levels for the patients younger than 1-year-old were very low compared to other age groups.

ABSTRACT

Objective: The cut-off values for the skin prick test diameters and cow’s milk-specific IgE measurements are used to predict the result of the oral food challenge test for the diagnosis of cow’s milk allergy. This study aimed to determine the diagnostic values of skin prick test and cow’s milk-specific IgE according to age groups and compare the diagnostic powers of these methods.

Materials and Methods: In total, 153 children who had a preliminary diagnosis of cow’s milk allergy were evaluated. Group A (n = 90) consisted of cow’s milk allergy patients whose diagnosis was confirmed by a positive oral food challenge or a history of anaphylaxis. Group B (n = 63) was composed of patients with a negative oral food challenge. The demographic, clinical, and laboratory findings of 2 groups were compared.

Results: The cut-off points for cow’s milk-specific IgE and cow’s milk-skin prick test were determined as >2.12 kUA/L and >5 mm, respectively. The area under the curve was 0.844 for cow’s milk-skin prick test (sensitivity 73%, specificity 84%) and 0.745 for cow’s milk-specific IgE (sensitivity 67%, specificity 86%). The diagnostic power of skin prick test was determined to be higher when compared to cow’s milk-specific IgE (P=0.02). According to the predicted probability curves, decision points for cow’s milk-specific IgE and cow’s milk-skin prick test with 95% probability were determined as follows, respectively: for ≤24 months: 22 kUA/L, 11.3 mm; for >24 months: 44.1 kUA/L, 15.1 mm. The lowest cut-off value with a positive predictive value of 95% and a specificity of 96% was found in patients <1-year-old (>3.3 kUA/L).

Conclusion: The use of high probability diagnostic values of communities for specific IgE and skin prick test along with a significant clinical history may provide accurate and rapid diagnosis of cow’s milk allergy and facilitate patient follow-up.

Keywords: Children, cow’s milk allergy, decision point, skin prick test, specific IgE

INTRODUCTION

Cow’s milk allergy (CMA) is the most common (2%-3%) food allergy in children. It may develop by IgE-associated and/or non-associated immune-mediated mechanisms. Skin prick test (SPT), CM-specific IgE (sIgE) measurement, and the oral food challenge (OFC) test are used for the diagnosis of IgE-associated CMA. In CMA, the basis of treatment is the elimination of milk and milk products from the diet until tolerance development is the basis of treatment, and symptomatic treatment is adjusted based on clinical findings. It is classically known that the percentage of patients developing tolerance to CM increases by age; 45%-50% at the age of 1, 60%-75% at the age of 2, and 85% at the age of 3. Some
newer studies reported lower ratios of tolerance reaching at most to 70% (57%-68%) at the age of 16. The elimination diet has negative effects on the quality of life of both the patient and the family. Long-term elimination diets may cause nutritional disorders in these children. Thus, it is important to make the correct diagnosis before starting the elimination diet to prevent unnecessary dietary practices.

The OFC, which is the gold standard in the definitive diagnosis of CMA, is a troublesome test with the risk of anaphylaxis and should be performed in experienced centers. The increasing frequency of food allergies in recent years has made it even more important to evaluate patients quickly and avoid unnecessary OFC testing in appropriate cases. Cow’s milk-specific IgE and SPT are safer and frequently used in clinical practice, but the positive results sometimes show only allergic sensitization and may not correlate with the clinical findings.

Detection of cut-off values that predict the result of OFC test accurately for both tests would facilitate the diagnosis and follow-up of patients with CMA, especially when the conditions are not suitable for performing an OFC test. Children living in different countries have different dietary habits and food sensitivities. In our country, the most common food allergy is CMA, but there are few studies to determine cut-off values with high diagnostic power for SPT and CM-sIgE in children with CMA.

In this study, it was aimed to determine cut-off values for CM-SPT and CM-sIgE in different age groups and compare the diagnostic power of these tests in order to reduce the need for OFC in the diagnosis of CMA.

MATERIALS AND METHODS

Study Population and Selection Criteria

This is a retrospective methodological study that evaluated the diagnostic power of SPT and sIgE to predict OFC test results in other words presence of CMA diagnosis. The patients who had a sudden allergic reaction associated with intake of CM or some non-specific allergic complaints of unknown origin were investigated for IgE-associated CMA with SPT and CM-sIgE measurement. A total of 153 patients in whom cow’s milk sensitivity was determined by a positive result in 1 or both of these tests were included in the study. The patients underwent an OFC test unless there was a clear-cut history of anaphylaxis after milk ingestion. This study was carried out in accordance with the principles of the Helsinki Declaration. Ethics committee approval was received from the Ethics Committee of Ege University (number and date: 15-4/15, 2015) and written informed consent was provided by the parents or legal guardians of the patients.

Study Protocol

Hospital files of the patients were evaluated and demographic, clinical characteristics, laboratory findings (total lgE, SPTs, CM-specific IgE), and OFC test results were recorded.

The included patients were divided into 2 groups according to the presence of CMA.

Group A (n = 90) comprised IgE-mediated CMA patients who had a positive OFC result or a clear-cut history of anaphylaxis after milk ingestion diagnosed in accordance with guidelines.

Group B (n = 63) comprised patients who were found to be non-reactive to milk with a negative OFC test result.

Assessment Methods

Skin Prick Test

Skin prick tests were performed with fresh milk (1 drop of each fresh milk containing 3.5% fat). Single-peak lancets (1 mm diameter) (Stallerpoint, Stallergenes SA laboratories) were used to prick the skin. Histamine (10 mg/mL) was used as positive control and NaCl (0.9%) was used as negative control. A wheal size ≥ 3 mm larger than the negative control was accepted as positive.

Cow’s Milk-Specific Immunoglobulin E Measurement

The total serum IgE and CM-sIgE levels were measured using the CAP system–Fluorescent enzyme immunoassay (FEIA) (Pharmacia Upjohn, NJ, USA). Cow’s milk-sIgE titers > 0.35 kUA/L were defined as positive.

Oral Food Challenge Test Protocol

Oral food challenge tests were started using 0.1 mL diluted pasteurized CM with 3.3% protein content (1 : 10, milk : water) and were continued with increasing amounts of undiluted cow’s milk every 15–30 minutes until a reaction was noted. If no reaction occurred with total amount of 200 mL (6540 mg milk protein) of CM, the child continued to receive at least 200 mL of CM or CM-based formula for the next week, and the parents were instructed to observe the child for late reactions. Oral food challenge results were considered positive when objective symptoms such as urticaria, angioedema, airway obstruction signs, vomiting, and anaphylaxis were developed.

Statistical Analysis

Statistical analyses were performed using the Statistical Package for Social Sciences version 23.0 software (IBM Corp.; Armonk, NY, USA) and MedCalc Statistical Software trial version (MedCalcSoftware, Ostend, Belgium, 2016). Continuous variables were presented as mean ± standard deviation (SD) or median (minimum:maximum) according to the distribution pattern of variables. The assumption of normality was tested using Kolmogorov–Smirnov or Shapiro–Wilks tests. Whether the distribution of each variable in the data set fits the normal distribution was tested and variables that were not normally distributed were evaluated by non-parametric tests. Mann–Whitney U test was used in binary-independent group comparison.

Categorical variables were compared by chi-square test and Fisher’s exact test. In order to estimate the sensitivity and specificity of CM–sIgE and CM–SPT measurements for predicting CMA, receiver operator characteristic (ROC) curve analysis was performed. Area under the ROC curve values with 95% CIs were reported. Different cut-off values for sIgE with >95% PPV, >90% specificity, and highest sensitivity and specificity were determined and predicted probability curves were created. A P-value less than .05 was considered statistically significant.

In the present study, post hoc power analysis was performed considering the CM-SPT measurements for study groups. The
effect size value was calculated as $d = 1.28$. With this effect size calculated, the power value obtained from the study at the level of $\alpha = 0.05$ was determined as $>95\%$.

RESULTS

In the study, 153 children (61% male) with a median age of 12 (2 : 84) months were evaluated. The symptoms at presentation were urticaria (68.6%, $n = 105$), urticaria and angioedema (17%, $n = 26$), and respiratory distress (11.1%, $n = 17$). Five patients who had a history of anaphylaxis after exposure to CM were included in group A without performing an OFC test. The median reaction dose was 6.0 (0–98) mL (0.19 g milk protein) in patients with a positive OFC test. Uneasiness was an accompanying symptom in 18 (11.7%) of the patients. Concomitant diseases were atopic dermatitis (37.2%, $n = 57$), asthma (10.4%, $n = 16$), allergic rhinitis (6.5%, $n = 10$), and colitis (4%, $n = 6$).

Five patients who had a history of anaphylaxis after exposure to CM were included in group A without performing an OFC test. The median reaction dose was 6.0 (0–98) mL (0.19 g milk protein) in patients with a positive OFC test.

Two groups of patients with and without CMA (groups A and B) were similar in terms of age ($P = .58$) and gender ($P = .56$). Urticaria-angioedema symptom was more frequently seen ($P < .01$) in group A, while frequencies of other symptoms at presentation ($P > .05$) and concomitant diseases ($P > .05$) were similar in 2 groups. There was no difference in median total IgE levels ($P = .06$) and wheal diameters of histamine ($P = .76$) between 2 groups. The median CM-SPT wheal diameter ($P < .001$) and CM-sIgE level ($P < .001$) were higher in group A (Table 1).

Group A patients were grouped according to age as $\leq 24$ and $>24$ months old. Two groups had similar presenting symptoms except uneasiness which was more frequent in patients $\leq 24$ months old (16% vs. 0%, $P < .001$). Concomitant asthma was more frequent in patients $>24$ months old (24.4% vs. 5.4%, $P < .001$), while atopic dermatitis was more frequent in patients $\leq 24$ months old (43% vs. 22%, $P = .01$). Histamine and CM wheal diameters in SPT were similar between 2 groups. Total IgE and CM-sIgE levels were higher in patients $>24$ months old than in patients $\leq 24$ months old (respectively, total IgE:190 (4.36:2142) kU/L, 67.50 (0.01:1584) kU/L, $P < .001$; CM-sIgE: 2.10 (0.03:100) kUA/L, 1.70 (0.01:79.10) kUA/L, $P = .04$) (Table 2).

Receiver Operator Characteristic Curve Analysis

Receiver operator characteristic (ROC) curve analysis was performed in the whole group and 2 groups according to age ($\leq 24$ and $>24$ months old). In the whole group, ROC curve analysis was performed to estimate the sensitivity and specificity of CM-SPT and CM-sIgE for predicting the presence of CMA. The cut-off points for CM-sIgE and CM-SPT were determined as $>2.12$ kUA/L and $>5$ mm, respectively.

The area under the curve (AUC) for CM-SPT was 0.844 (sensitivity 73%, specificity 84%), showing that CM-SPT $> 5$ mm was significantly related to an increased risk of the presence of CMA. The AUC for CM-sIgE was 0.745 (sensitivity 67%, specificity 86%).

When the OFC was taken as a basis, comparison of the AUCs showed that the diagnostic power of CM-SPT was significantly higher than CM-sIgE ($P = .02$) (Figure 1, Table 3).

Among the patients $\leq 24$ months old, the AUC for CM-SPT was 0.838 (sensitivity 71%, specificity 84%), and AUC for CM-sIgE was 0.736 (sensitivity 62%, specificity 86%). The difference between the diagnostic power of 2 tests was significant ($P = .04$) (Figure 1, Table 3).

In the patients $>24$ months old, CM-sIgE and CM-SPT were not found to be superior to each other ($P = .41$) in the diagnosis of CMA (Figure 1, Table 3).

**Predicted Probability Curves Showing Positive Cow’s Milk Challenge Test Results**

We calculated the predicted probabilities for a positive clinical reactivity at a given CM-sIgE level using the logistic regression model proposed by Sampson.29 According to the predicted

---

**Table 1.** Demographic, Clinical, and Laboratory Features of the Patients According to the Groups

|                        | Group A ($n = 90$) | Group B ($n = 63$) | $P$  |
|------------------------|-------------------|-------------------|------|
| Median age (months)    | 12 (2 : 74)       | 12 (4 : 84)       | .580 |
| Sex distribution (male)| 59% ($n = 53$)    | 63.5% ($n = 40$)  | .566 |
| Uneasiness            | 9 (10%)           | 9 (14.30%)        | .418a|
| Urticaria              | 54 (80%)          | 51 (80%)          | .509a|
| Urticaria and angioedema| 22 (24.40%)     | 4 (6.30%)         | .003a|
| Anaphylaxis            | 5 (5.6%)          | 0                 | .078a|
| Respiratory distress   | 9 (10%)           | 8 (12.6%)         | .875a|
| Colitis                | 4 (4.4%)          | 7 (11.1%)         | .999a|
| Allergic rhinitis      | 3 (3.3%)          | 7 (11.1%)         | .933a|
| Asthma                 | 9 (10%)           | 7 (11%)           | .825a|
| Atopic dermatitis      | 34 (37.8%)        | 23 (36.5%)        | .873a|
| Median total IgE (kU/L)| 114.50 (3.29 : 2142) | 64.70 (0.01 : 1706) | .061 |
| Median histamine-SPT (mm)| 6 (3 : 13) | 6 (3 : 12) | .766 |
| Median CM-SPT (mm)     | 9 (0 : 35)        | 0 (0 : 12)        | < .001 |
| Median CM-sIgE (kUA/L) | 3.87 (0.01 : 100) | 1.04 (0.01 : 40.30) | < .001 |

*Chi-square test;  
Fisher’s exact test.

SPT, skin prick test;  
CM, cow’s milk;  
sIgE, specific immunoglobulin E.

---

**Table 2.** Laboratory Features of the Patients According to the Age of the Patients

| Age of Patients | Median total IgE (kU/L) | Median histamine-SPT (mm) | Median CM-SPT (mm) | Median CM-sIgE (kUA/L) | $P$  |
|-----------------|-------------------------|---------------------------|-------------------|------------------------|------|
| $\leq 24$ months ($n = 112$) | 67.50 (0.01 : 1584) | 6 (3 : 12) | 5 (0 : 35) | 1.70 (0.01 : 79.10) | < .001*a  |
| $>24$ months ($n = 41$) | 190 (4.36 : 2142) | 6 (4 : 13) | 5 (0 : 20) | 2.10 (0.03 : 100) | .542a  |

*Mann-Whitney U test.  
SPT, skin prick test;  
CM, cow’s milk;  
sIgE, specific immunoglobulin E.  

probability curves, decision points for CM-sIgE and CM-SPT with 95% probability were determined as follows, respectively: whole group 32.6 kUA/L, 12.4 mm; ≤24 months 22 kUA/L, 11.3 mm; >24 months 44.1 kUA/L, 15.1 mm (Figure 2, 3).

Immunoglobulin E Cut-off Levels for the Prediction of Clinical Reactivity
The CM-sIgE cut-off values were examined separately for ages from 1 to 5 years. Three separate CM-sIgE levels that correspond to decision points with >95% PPV, >90% specificity, and highest sensitivity and specificity were found for each group. The lowest cut-off value with a PPV of 95% and a specificity of 96% was in patients <1-year-old (>3.3 kUA/L) (Table 4).

DISCUSSION
In the previous studies carried out, quite different CM-sIgE levels and CM-SPT induration diameters were reported as cut-off values to predict CMA. In this study, significant cut-off values for CM-sIgE and SPT, with 95% decision points predicting CMA, and the diagnostic power of these tests were investigated. Sampson et al reported that CM-sIgE levels diagnostic for CMA with 95% PPV were 5 kUA/L for patients <2 years old and 15 kUA/L for patients >2 years old. In this study, higher cut-off levels (>7.6 kUA/L) with 91% PPV were determined in patients ≤2 years old. PPV and specificity were found to be lower under this level. But in patients <1-year-old, a quite lower cut-off (>3.3 kUA/L) had a PPV of 95% and specificity of 96%. This result suggests that patients younger than 1-year-old should be evaluated with separate cut-off values. The cut-off level of >14.2 kUA/L was significant for CMA diagnosis with 93% PPV and 95% specificity in patients >2 years old similar to Sampson’s study. In patients over 5 years of age, the PPV and specificity for this cut-off even reached 100%.

In different studies, CM-sIgE levels corresponding to 90%-95% at predicted probability curves were found to be in good correlation with clinical reactivity and helpful in making a diagnosis. The CM-sIgE levels diagnostic for CMA with 90% predicted probability were determined to be higher in children younger than 2 years (31.4 kUA/L) than in children older than 2 years (10.1 kUA/L) by Kim et al. Çelik-Bilgili et al reported higher cut-off levels with 90% predictive values in children younger than 1 year (25.8 kUA/L) and at all ages (68.8 kUA/L). This broad range of cut-off values for CM-sIgE found in different studies may be due to the differences in the study groups in terms of diagnosis, age, and disease severity distributions, as well as differences in the community characteristics such as the frequency of allergy, onset time, and consumption amount of that supplementary food.

![Figure 1. ROC curves for CM-sIgE (kUA/L) and CM-SPT (mm) in the whole group (A), in children ≤24 months (B), and >24 months (C).](image)

### Table 3. Performance Characteristics of Cow’s Milk-sIgE Levels and Cow’s Milk-SPT Diameters in the Determination of CMA (Whole Group and 2 Age-Based Groups)

| Performance Characteristics | Whole Group | ≤24 months | >24 months |
|-----------------------------|-------------|------------|------------|
| Cut-off value               | CM-sIgE (kUA/L) | CM-SPT (mm) | CM-sIgE (kUA/L) | CM-SPT (mm) | CM-sIgE (kUA/L) | CM-SPT (mm) |
| Sensitivity (%)             | 67          | 62         | 86         | 86         | 87         | 88         |
| Specificity (%)             | 86          | 86         | 86         | 86         | 87         | 88         |
| PPV (%)                     | 87          | 88         | 88         | 88         | 87         | 88         |
| NPV (%)                     | 64          | 64         | 64         | 64         | 64         | 64         |
| AUC (±)                     | 0.745       | 0.736      | 0.838      | 0.735      | 0.886      |

SPT, skin prick test; CM, cow’s milk; sIgE, specific immunoglobulin E; PPV, positive predictive; NPV, negative predictive value; AUC, area under the curve.
In this study, CM-sIgE cut-off levels with 100% PPV and >90% specificity were displayed for different age groups (Table 4, values in the second line for each age group). We propose that these values can be used for CMA diagnosis without performing OFC test.

Yavuz et al. also reported CM-sIgE levels with 95% diagnostic value for CMA in Turkish children, but cut-off levels were lower than our study. They found that in children <2 years old, the cut-off level significant with 95% PPV and 94% specificity (9.3 kUA/L) was also supported by predictive probability curves.

![Figure 2. The predicted probability curves for CM-sIgE (A) and CM-SPT (B) in the whole group. SPT, skin prick test; CM, cow’s milk; sIgE, specific immunoglobulin E.](image)

![Figure 3. The predicted probability curves for CM-sIgE and CM-SPT in children ≤24 months (A,B) and > 24 months (C,D). SPT, skin prick test; CM, cow’s milk; sIgE, specific immunoglobulin E.](image)
Diagnostic Laboratory Findings in CMA

Table 4. Cow’s Milk-sIgE Cut-off Values for Prediction of Clinical Reactivity

| Age, Years | n  | Performance Characteristics | AUC  | Cut-off | Sens | Spec | PPV  | NPV  | P   |
|------------|----|-----------------------------|------|---------|------|------|------|------|-----|
| <1         | 68 | >95% PPV                     | >3.33| 45      | 96   | 95   | 55   | <.001|     |
|            |    | >90% Spec.                   | 0.743| >20.30  | 10   | 100  | 100  | 44   |     |
|            |    | Highest Sens. & Spec.        | >2.10| 63      | 89   | 89   | 63   |     |     |
| ≥1         | 85 | >95% PPV                     | >25.90| 26      | 97   | 93   | 48   |     | <.001|
|            |    | >90% Spec.                   | 0.748| >40.30  | 18   | 100  | 100  | 46   |     |
|            |    | Highest Sens. & Spec.        | >2.40| 68      | 86   | 87   | 65   |     |     |
| <2         | 108| >95% PPV                     | >7.60| 31      | 95   | 91   | 48   |     | <.001|
|            |    | >90% Spec.                   | 0.721| >25.90  | 9    | 100  | 100  | 42   |     |
|            |    | Highest Sens. & Spec.        | >2.12| 60      | 86   | 87   | 59   |     |     |
| ≥2         | 45 | >95% PPV                     | >14.20| 52      | 95   | 93   | 61   |     | <.001|
|            |    | >90% Spec.                   | 0.830| >40.30  | 28   | 100  | 100  | 53   |     |
|            |    | Highest Sens. & Spec.        | >2.40| 84      | 90   | 91   | 82   |     |     |
| <3         | 120| >95% PPV                     | >7.60| 34      | 95   | 93   | 46   |     | <.001|
|            |    | >90% Spec.                   | 0.737| >25.90  | 13   | 100  | 100  | 40   |     |
|            |    | Highest Sens. & Spec.        | >2.12| 63      | 86   | 89   | 58   |     |     |
| ≥3         | 33 | >95% PPV                     | >14.20| 64      | 95   | 90   | 78   |     | <.001|
|            |    | >90% Spec.                   | 0.872| >40.30  | 36   | 100  | 100  | 68   |     |
|            |    | Highest Sens. & Spec.        | >2.40| 86      | 89   | 86   | 90   |     |     |
| <5         | 141| >95% PPV                     | >25.90| 18      | 98   | 94   | 44   |     | <.001|
|            |    | >90% Spec.                   | 0.737| >40.30  | 11   | 100  | 100  | 42   |     |
|            |    | Highest Sens. & Spec.        | >2.12| 66      | 86   | 88   | 62   |     |     |
| ≥5         | 12 | >95% PPV                     | >1.53| 80      | 86   | 80   | 86   |     | <.001|
|            |    | >90% Spec.                   | 0.886| >14.20  | 40   | 100  | 100  | 70   |     |
|            |    | Highest Sens. & Spec.        | >1.21| 100     | 71   | 71   | 100  |     |     |
| All        | 153| >95% PPV                     | >25.90| 19      | 98   | 94   | 46   |     | <.001|
|            |    | >90% Spec.                   | 0.745| >40.30  | 11   | 100  | 100  | 44   |     |
|            |    | Highest Sens. & Spec.        | >2.12| 67      | 86   | 87   | 64   |     |     |

Sens, sensitivity; Spec, specificity; AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value.

with 95% decision points (11.1 kUA/L), whereas, in our study, the value significant with 95% predicted probability (22 kUA/L) was closer to the diagnostic value (>25.9 kUA/L); 100% PPV and 100% specificity) instead of 95% PPV. Also, in children >2 years old, they found lower significant and diagnostic levels (>4 kUA/L, with 93% PPV, 91% specificity) compared to our study (>14.2 kUA/L, with 93% PPV, 95% specificity).24 But according to the predicted probability curves, decision points for CM-sIgE with 95% probability were higher in our study for >24 months (44.1 kUA/L).

As in CM-sIgE, induration diameters in CM-SPT significant for CMA diagnosis with >95% PPV were detected in a wide range (5–15 mm) in different studies.25-28 Sampson28 reported that 10 mm induration diameter is considered significant. In our study, induration diameters diagnostic for CMA with 95% predicted probability were found as 11.3 mm for patients ≤2 years old and 15.1 mm for patients >2 years old. The diagnostic value found for the whole group (12.4 mm) was closer to the value of patients ≤2 years old, likely due to the early diagnosis in majority of the study population.

This study is also important because it compared the diagnostic strengths of CM-sIgE and CM-SPT in CMA. When ROC curves for CM-sIgE and CM-SPT were compared, SPT was found to be superior in the diagnosis of CMA in patients ≤24 months of age. Therefore, SPT can be suggested to be the first choice in this group. In those >24 months of age, diagnostic power of 2 tests was similar. This result is important for health centers that cannot do CM-sIgE testing and that would use the high predictive probability values in SPT for the diagnosis of CMA. It also shows how sensitive the SPT is in young children.

This is a study that evaluates CM-sIgE and SPT together and compares them in predicting the presence of CMA. Results that would show the presence of clinical signs at high probability were calculated. We determined the CM-sIgE level of 32.6 kUA/L and CM-SPT induration diameter of 12.4 mm as threshold values for CMA diagnosis (with 95% predicted probability) when the age is not taken into account.

In this study, different and heterogenous CM-sIgE cut-off levels at high specificity and PPV were found for different ages. But prominently, lower cut-off level that was found for the patients younger than 1 year suggested that this group should be evaluated as a separate and special group.

The present study has some limitations. We did not perform double-blind, placebo-controlled OFC, which is the gold standard. Instead, the open OFC was applied and only the objective findings were recorded. Yet, we had no doubt about the diagnosis of IgE-mediated CMA because all patients in group A had a reaction history after the intake of milk and/or milk products.

Another limitation of the study is that there are differences between age groups in terms of number of patients and...
diagnosis. In addition, the fact that the patients included in the study were high-risk patients who applied to the pediatric allergy outpatient clinic and had an increased probability of diagnosis may have caused higher cut-off values compared to the general population.

**CONCLUSION**

In this study, we determined the CM-SPT and CM-sIgE cut-off values in different age groups that can be used to predict the result of OFC test results. The cut-off points for CM-sIgE and CM-SPT were determined as >2.12 kUA/L and >5 mm, respectively. According to the predicted probability curves, decision points for CM-sIgE and CM-SPT with 95% probability were determined as follows, respectively: for ≤24 months 22 kUA/L, 11.3 mm; for >24 months 44.1 kUA/L, 15.1 mm. Additionally, we showed that the lower cut-off values for CM-sIgE were significant under the age of 1 (>3.3 kUA/L). The use of high probability diagnostic values for CM-sIgE and SPT, along with a significant clinical history, strengthens the diagnosis of CMA and directs the clinician by predicting the OFC results. Considering that different decision points have been determined in different societies, it would be appropriate to use the diagnostic decision values obtained in cases with CMA pre-diagnosis.

**Ethics Committee Approval:** This study was approved by Ethics Committee of Ege University, (Approval No: 15-4/15, 2015).

**Informed Consent:** Written informed consent was provided by the parents or legal guardians of the patients.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept – N.C.G., E.D.; Design – N.C.G., S.E.A., E.D.; Supervision – F.G., R.T.; Materials – N.C.G., S.E.A., F.G., C.M.B.; Data collection &/or processing – N.C.G., M.Aç, C.M.B.; Analysis and/or interpretation – N.C.G., E.D.

**Declaration of Interests:** The authors have no conflicts of interest to declare.

**Funding:** The authors declared that this study received no financial support.

**REFERENCES**

1. Hast A. Frequency of cow’s milk allergy in childhood. Ann Allergy Asthma Immunol. 2002;89(6):33–37. [CrossRef]
2. Lifschitz C, Szajewska H. Cow’s milk allergy: evidence-based diagnosis and management for the practitioner. Eur J Pediatr. 2015;174(2):141-150. [CrossRef]
3. Sicherer SH. Food allergy: when and how to perform oral food challenges. Pediatr Allergy Immunol. 1999;10(4):226-234. [CrossRef]
4. Warner JO, Rosario N, Potter P, Wahn U, Baena-Cagnani CE. A children’s asthma charter. Pediatr Allergy Immunol. 2010;21(1-Part):1-2. [CrossRef]
5. Wang J, Sampson HA. Food allergy. J Clin Invest. 2011;121(3):827-835. [CrossRef]
6. Hast A, Halken S, Jacobsen HP, Christensen AE, Herskind AM, Ple snkr K. Clinical course of cow’s milk protein allergy, intolerance and atopic diseases in childhood. Pediatr Allergy Immunol. 2002;13(s15):23-28. [CrossRef]
7. Skripak JM, Matsui EC, Mudd K, Wood RA. The natural history of IgE-mediated cow’s milk allergy. J Allergy Clin Immunol. 2007;120(5):1172-1177. [CrossRef]
8. Elizur A, Rajuan N, Goldberg MR, Lesnho M, Cohen A, Katz Y. Natural course and risk factors for persistence of IgE-mediated cow’s milk allergy. J Pediatr. 2012;161(3):482-487.e1. [CrossRef]
9. García-Ara C, Boyano-Martínez T, Díaz-Peña JM, Martín-Muñoz F, Reche-Frutos M, Martín-Esteban M. Specific IgE levels in the diagnosis of immediate hypersensitivity to cow’s milk protein in the infant. J Allergy Clin Immunol. 2001;107(1):185-190. [CrossRef]
10. Cummings AJ, Knibb RC, King RM, Lucas JS. The psychosocial impact of food allergy and food hypersensitivity in children, adolescents and their families: a review. Allergy. 2010;65(8):933-945. [CrossRef]
11. Finsterman AE, Knulst AC, Meijer Y, Brujinzeel-Koomen CAFM, Passmans SGMA. Acute allergic reactions in children with AEDS after prolonged cow’s milk elimination diets. Allergy. 2006;61(5):370-374. [CrossRef]
12. Fleischer DM, Conover-Walker MK, Christie L, Burks AW, Wood RA. Peanut allergy: recurrence and its management. J Allergy Clin Immunol. 2004;114(5):1195-1201. [CrossRef]
13. Sicherer SH, Sampson HA. Food allergy. J Allergy Clin Immunol. 2006;117(2):5470-5475. [CrossRef]
14. Bindslev-Jensen C, Ballmer-Weber BK, Bengtsson U, et al. Standardization of food challenges in patients with immediate reactions to foods—position paper from the European Academy of Allergology and Clinical Immunology. Allergy. 2004;59(7):690-697. [CrossRef]
15. Nowak-Wegrzyn A, Assa’ad AH, Bahna SL, et al. Adverse reactions to food committee of American Academy of Allergy, Asthma & Immunology. Work Group report: oral food challenge testing. J Allergy Clin Immunol. 2009;123(suppl):365-383.
16. Mehl A, Niggemann B, Keil T, Wahn U, Beyrer K. Skin prick test and specific serum IgE in the diagnostic evaluation of suspected cow’s milk and hen’s egg allergy in children: does one replace the other? Clin Exp Allergy. 2012;42(8):1266-1272. [CrossRef]
17. Muraro A, Roberts G, Clark A, et al. The management of anaphylaxis in childhood: position paper of the European Academy of Allergology and Clinical Immunology. Allergy. 2007;62(8):857-871. [CrossRef]
18. Simons FE, Arduoso LR, Bilò MB, et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol. 2011;127(3):587-93.e1. [CrossRef]
19. Vandenberglos Y, Koletzko S, Isolauri E, et al. Guidelines for the diagnosis and management of cow’s milk protein allergy in infants. Arch Dis Child. 2007;92(10):902-908. [CrossRef]
20. Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol. 2001;107(5):891-896. [CrossRef]
21. Celikt-Bilgili S, Mehl A, Verstege A, et al. The predictive value of specific immunoglobulin E levels in serum for the outcome of oral food challenges. Clin Exp Allergy. 2005;35(3):268-273. [CrossRef]
22. Yavuz ST, Buyuktiryaki B, Şahiner UM, et al. Factors that predict the clinical reactivity and tolerance in children with cow’s milk allergy. Ann Allergy Asthma Immunol. 2013;110(4):284-289. [CrossRef]
23. Verstege A, Mehl A, Rolinck-Werninghaus C, et al. The predictive value of the skin prick test as a tool for the outcome of oral food challenges. Clin Exp Allergy. 2005;35(9):1220-1226. [CrossRef]
24. Payot F, Berthiller J, Kassai B, Brunet AS, Villard-Truc F, Lachaux A. Practical interest of both skin prick test and specific IgE in the evaluation of tolerance acquisition in IgE mediated cow’s milk allergy (CMA). A clinical retrospective study in a cohort of 184 children. Allergol Immunopathol (Madr). 2014;42(5):395-401. [CrossRef]
25. Calvani M, Alessandri C, Frediani T, et al. Correlation between skin prick test using commercial extract of cow's milk protein and fresh milk and food challenges. *Pediatr Allergy Immunol*. 2007;18(7):583-588. [CrossRef]

26. Sporik R, Hill DJ, Hosking CS. Specificity of allergen skin testing in predicting positive open food challenges to milk, egg and peanut in children. *Clin Exp Allergy*. 2000;30(11):1540-1546. [CrossRef]

27. Calvani M, Berti I, Fiocchi A, et al. Oral food challenge: safety, adherence to guidelines and predictive value of skin prick testing. *Pediatr Allergy Immunol*. 2012;23(8):755-761. [CrossRef]

28. Mehl A, Rolink-Wherninghaus C, Staden U, et al. The atopy patch test in the diagnostic workup of food-related symptoms in children. *J Allergy Clin Immunol*. 2006;118:923-929.